NATAP: Generics/New Drug R&D

[Guest guest]

Subject: NATAP: Generics/New Drug R & DGenerics market to boom as blockbusters go off-patent; 'generics slow down in 2013' - (01/18/12) "Do generic drugs work as well as the expensive ones?"pharmaceutical companies are more eager than ever to strike partnerships with biotechs." "not everything is expected to be rosy for the generics market, especially after 2013, when patent expiries will be significantly lower.""legal innovation isn't going to put new drugs in the pipeline.....While

R & D spending has climbed over the last decade, reaching about $1.2 billion per drug from about $230 million in the 1980s, the yield from that expense has been low. The FDA says it approved only 21 new medicines last year, and some companies, like Pfizer, are slashing R & D spending. The lack of innovation has concerned the Obama administration"